| |

Surgical Treatment Options for Mesothelioma

ByHolly Zink
Surgical Treatment Options for Mesothelioma

For some patients with mesothelioma, aggressive surgical treatment can help them live longer than other treatment options.

This is the finding of a study published in the Journal of Thoracic and Cardiovascular Surgery. The authors focused on a specific type of surgery called “cytoreductive surgery” that is done in both the chest and belly area.

Surgery Provides Hope for Cure

Mesothelioma is a deadly cancer caused by asbestos exposure. The type of treatment for mesothelioma depends on many factors. The location of the cancer, the type of mesothelioma, and the health of the patient are some of these key factors.

For patients who are healthy enough, surgery provides the best hope for a cure. Cytoreductive surgery is a type of procedure that aims to remove all cancerous tissue. When mesothelioma grows in the lungs, this type of surgery can either be “extrapleural pneumonectomy” (EP) or “extended pleurectomy/decortication” (ePD).

When a patient has an EP procedure, as much of the affected lung tissue is removed as possible. Sometimes the entire lung is removed to get rid of all cancer cells. With an ePD procedure, the doctor tries to leave as much of the lungs in place as possible.

Aggressive Surgical Options

The scientists in this study looked at medical records of 440 patients with mesothelioma who had a cytoreductive surgery between 2014 and 2021. They found that out of these 440 patients, only 14 had the surgery in both the chest and belly and most of them had the chest surgery first.

The scientists found that the average survival time for all patients was 33.6 months and that 5 years after diagnosis, 20% of patients were still alive.

They also found that patients who had ePD had better survival than patients who had EP. Patients who had an ePD procedure had an average survival time of 58.2 months. Patients who had EP had an average survival time of only 13.5 months.

The conclusion of the study is that for a small group of patients with mesothelioma in both the chest and belly, they can live longer with aggressive surgery. The study also showed that patients who have ePD surgery, which tries to preserve the lung, had better results compared to the EP surgery, which removes the lung.

Source

Ripley RT, Holmes HM, Whitlock RS, et al. Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy [published online ahead of print, 2022 Dec 14]. J Thorac Cardiovasc Surg. 2022;S0022-5223(22)01338-1. doi:10.1016/j.jtcvs.2022.11.035. https://pubmed.ncbi.nlm.nih.gov/36740497/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…